Anti inhibitor Coagulant Complex

Anti inhibitor Coagulant Complex Brand Names

FEIBA | FEIBA NF | Feiba NF Immuno | FEIBA VH Immuno

What is Anti inhibitor Coagulant Complex

Anti- inhibitor coagulant complex (AICC) is derived from human plasma.

Anti inhibitor coagulant complex is similar to prothrombin complex concentrates (PCCs or factor IX complexes), but AICC has undergone in vitro activation resulting in an increased amount of activated and precursor vitamin K-dependent clotting factors (factors II, VII, IX, and X).

Anti inhibitor coagulant complex is used as coagulation factor bypass therapy in patients with hemophilia with inhibitors or in patients with acquired inhibitors to other clotting factors.

In patients with high inhibitor titers (more than 10 Bethesda Units) or who rapidly develop inhibitors following exposure to factor products (high responders), AICC provides activated clotting factors and controls bleeding in about 80% to 90% of patients with 1 or 2 doses.

FEIBA products contain factors II, IX, and X, which are mainly inactivated, and factor VII, which is mainly activated.

FEIBA contains only trace amounts of factors of the kinin generating system and no heparin.

The activity of FEIBA is expressed in arbitrary units; 1 unit of activity is defined as the amount of FEIBA that shortens the aPTT of high titer factor VIII inhibitor reference plasma to 50% of the blank value.

These products undergo processes that are designed to reduce the risk of infectious contamination.


  1. bleeding prophylaxis
  2. dabigatran reversal
  3. factor VII deficiency
  4. hemarthrosis
  5. hemophilia A
  6. hemophilia B
  7. hemorrhage
  8. rivaroxaban reversal
  9. surgical bleeding
  10. von Willebrand’s disease

For the control and prevention of bleeding episodes (i.e., hemorrhage, hemarthrosis), perioperative management (surgical bleeding), and routine bleeding prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or hemophilia B with inhibitors or patients with acquired inhibitors to other factors including patients with factor VII deficiency† or von Willebrand’s disease

Side Effects

  1. anaphylactoid reactions
  2. anemia
  3. angioedema
  4. bronchospasm
  5. chest pain (unspecified)
  6. chills
  7. diarrhea
  8. disseminated intravascular coagulation (DIC)
  9. dizziness
  10. drowsiness
  11. dysgeusia
  12. dyspnea
  13. fever
  14. flushing
  15. hot flashes
  16. hypertension
  17. hypoesthesia
  18. hypotension
  19. infection
  20. infusion-related reactions
  21. injection site reaction
  22. malaise
  23. myocardial infarction
  24. nausea
  25. pruritus
  26. pulmonary embolism
  27. sinus tachycardia
  28. stroke
  29. thromboembolism
  30. urticaria
  31. vomiting
  32. wheezing

Monitoring Parameters

  • activated partial thromboplastin time (APTT)
  • clotting inhibitor titers


  • breast-feeding
  • children
  • disseminated intravascular coagulation (DIC)
  • myocardial infarction
  • pregnancy
  • thrombocytopenia
  • thromboembolism
  • viral infection


  • Aminocaproic Acid
  • Emicizumab
  • Tranexamic Acid

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

Scroll to Top